Pharma BD Deal Intelligence
AbbVie swooped in to win a bidding war for ImmunoGen, outmaneuvering at least one other suitor. The competitive auction suggests strong market validation of…
Global Elahere net revenues were $690 million for full-year 2025 (an increase of 1.5% reported); Q4 2025 net revenues were $182 million (+22.6% reported).…
Global Elahere net revenues were $198 million in Q1 2026, an increase of 10.7% on a reported basis. Release dated April 29, 2026.
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
AbbVie acquired ImmunoGen for approximately $10.1 billion ($31.26 per share) in an all-cash merger, gaining Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate approved for FRα-positive platinum-resistant ovarian cancer.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / ImmunoGen Inc. (this deal) | 2023 | $10.1B | 69 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
| AbbVie Inc. / MedinCell S.A. | 2024 | $1.9B | 61 |
← Browse all deals · How we score deals
More: 2023 deals · AbbVie Inc. deals · Oncology deals